Freeze All on Oocyte Maturatin by Gonadotropin Agonist Versus Human Chorionic Gonadotroipin

• Sponsor: Aljazeera Hospital (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT04749979
• Collaborator: Cairo University (Other)
• Enrollment: 100
• Location: 1
• Arms: 2
• Anticipated Duration (Months): 4.8
• Patients Per Site Per Month: 20.8

Study Details

Study Description

Brief Summary

Estradiol valerate in the form of cycloprogenova™ (white tablet only) was started on day 2 or 3 of cycle with oral dose 4 mg divided on 2 doses in addition to Aspocid 75 mg once daily with folic acid 500 mcg once daily.

Condition or Disease	Intervention/Treatment	Phase
Infertility	Drug: Agonist (decapeptyl ); Drug: HCG ( eg. Choriomon )	N/A

Detailed Description

U/S was done on day 9 or 10 of cycle to assess endometrial thickness, then every other day until endometrial thickness of 8 mm or more is reached and when endometrial thickness reaches 8 mm or more FET was planned. Progesterone in the form of prontogest™ 400 mg vaginal suppository twice dTwo to Four Day 5 Embryos was transferred

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 100 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Freeze All on Oocyte Maturatin by Gonadotropin Agonist Versus Human Chorionic Gonadotroipin in IVF Cycles
• Anticipated Study Start Date: Feb 5, 2021
• Anticipated Primary Completion Date: Jun 25, 2021
• Anticipated Study Completion Date: Jul 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: giving agonist ( eg. decapeptyl ) Giving women agonist	Drug: Agonist (decapeptyl ); giving agonist
Active Comparator: Giving HCG (eg. choriomon ) Giving women HCG	Drug: HCG ( eg. Choriomon ); giving HCG

Outcome Measures

Primary Outcome Measures

1. the number of good quality embryos [within 5 months]

   how many good quality embryos

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 42 Years
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• PCOS patients according to Rotterdam criteria

• Female age between 20 and 40 years.

• Primary or secondary infertility.

• Body mass index (BMI) between 18 and 40 kg/m2.

Exclusion Criteria:

• Ovarian endometriosis.

• Ovarian cysts before induction.

• Known uncontrolled endocrinal abnormalities (like hypo or hyperthyroidism)

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Aljazeera( Al Gazeera) hospital	Giza		Egypt

Sponsors and Collaborators

• Aljazeera Hospital
• Cairo University

Investigators

• Principal Investigator: Mahmoud Alalfy, PhD, Algezeera hospitaland National Research Centre ,Egypt

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Aljazeera Hospital
• ClinicalTrials.gov Identifier: NCT04749979
• Other Study ID Numbers: Oocyte
• First Posted: Feb 11, 2021
• Last Update Posted: Feb 11, 2021
• Last Verified: Feb 1, 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Infertility; Triptorelin Pamoate

Study Results

No Results Posted as of Feb 11, 2021